Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on May 6, 2025
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer
GlobeNewswire
·
May 6, 2025
Topline data shows statistically significant improvement in overall survival in elraglusib plus GnP combination arm versus GnP control arm Elraglusib/GnP combination arm demonstrated substantial improvement in median overall survival since the last data …
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 6, 2025
On track to announce the primary endpoint results from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; planning for Biologics License Application (BLA) submission for atacicept accelerated approval to the U.S. FDA in 4Q …
Krystal Biotech Announces First Quarter 2025 Financial and Operating Results
GlobeNewswire
·
May 6, 2025
VYJUVEK approved in Europe for the treatment of DEB patients from birth $88.2 million in 1Q VYJUVEK revenue and $429.4 million since launch in Q3 2023 Second ophthalmic program in clinic - KB801 for the treatment of neurotrophic keratitis Upcoming clinical …
Catheter Precision, Inc. Completes Acquisition of Cardionomic Heart Failure Assets
GlobeNewswire
·
May 6, 2025
FORT MILL, S.C., May 06, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that its 82% …
BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study
GlobeNewswire
·
May 6, 2025
CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) and Elevated Markers of Cardiac Stress Dr. Amish Raval, Professor of Medicine at the University of …
Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
GlobeNewswire
·
May 6, 2025
GAL-101 well tolerated; excellent safety and pharmacokinetic profile strongly supports oral administration Next arms of study, including multiple ascending dose (MAD), underway and expected to complete in late 2025 Planned indications include dry age- …
VAXIL: SHARE CONSOLIDATION
GlobeNewswire
·
May 6, 2025
Not for distribution by US newswire or in United States TORONTO, May 06, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), is pleased to make the following updates regarding the Company’s activities. Vaxil announces …
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
GlobeNewswire
·
May 6, 2025
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, …
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
GlobeNewswire
·
May 6, 2025
GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 13, 2025. Altimmune management …
OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
May 6, 2025
-- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data -- Expansion of the Company’s PI3Ka franchise with the planned announcement of a pan- …
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress
GlobeNewswire
·
May 6, 2025
- Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. …
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
GlobeNewswire
·
May 6, 2025
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Bank of …
CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 6, 2025
‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ., May 06, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on …
Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call
GlobeNewswire
·
May 6, 2025
CELEBRATION, Fla., May 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate …
Bioventus Reports First Quarter Financial Results
GlobeNewswire
·
May 6, 2025
Q1 reported revenue of $123.9 million declined 4.3%; Organic* revenue advanced 5.0% First quarter net loss was $0.04 per share compared to a loss of $0.08 in the prior-year period Non-GAAP earnings* of $0.08 per share increased 33% Company reiterated …
Neuronetics Reports First Quarter 2025 Financial and Operating Results
GlobeNewswire
·
May 6, 2025
MALVERN, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of …
Kraig Biocraft Laboratories Successfully Completes March/April Production Cycle; May Production Now Underway
GlobeNewswire
·
May 6, 2025
ANN ARBOR, Mich., May 06, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it has successfully completed its March/April spider silk …
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
GlobeNewswire
·
May 6, 2025
PRINCETON, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody- …
The Joint Corp. Strengthens Management Appointing SVP Legal and SVP Operations and Patient Experience
GlobeNewswire
·
May 6, 2025
- Franchising legal specialist Andra J. Terrell with 20 years of experience in global master, single-unit and multi-unit franchising; compliance strategy; and financing, mergers, acquisitions, and divestitures- - Franchise operations leader Eric Wyatt with …
Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004
GlobeNewswire
·
May 6, 2025
-- PAS-004 shows up to 91% inhibition of pERK, confirming substantial target engagement -- -- One patient in cohort 4A with stage 4 KRAS G12R mutated pancreatic cancer achieves over 5 months of stable disease with tumor volume reduction of -9.8% -- MIAMI, …